Nherera zita remushonga rinopihwa neFDA kune CART T-Cell Therapy A2B530 yekurapa cancer cancer.

Nherera zita remushonga rinopihwa neFDA kune CART T-Cell Therapy A2B530 yekurapa cancer cancer.

Share This Post

Muna Kurume 2024, kuburitswa kwenhau kwakataura kuti A2B530 (A2 Biotherapeutics), CAR T-cell therapy, yakapihwa Orphan Drug Designation yekurapa colorectal cancer inoratidzira carcinoembryonic antigen (CEA) uye yakarasikirwa neHLA-A * 02 kutaura muvanhu vane germline. heterozygous HLA-A*02 (+) chirwere.

Vatsvagiri vanofunga kuti autologous logic-gated cell therapy inogona kunanga bundu maseru ichidzivirira hutano. Izvi zvinodaro nekuti ine yakavakirwa-mukati yekuchengetedza switch iyo inogona kuchengetedza hutano hutano kubva mukukuvadzwa. Muchikamu che1/2 EVEREST-1 (NCT05736731) chidzidzo, pfungwa iyi ichaedzwa.

Unogona kuda kuverenga: CAR T-Cell kurapa muChina

Sarudzo yeFDA yekupa Orphan Drug Designation inosimbisa kukosha kukuru kusingakwane kwemishonga iri nani kune vanhu vane colorectal cancer,” akadaro William Go, MD, PhD, mukuru wekurapa weA2 Bio, mukuburitswa kwenhau. Iri zita rinotsigira vimbiso yedu yekushandisa yedu yekucheka-kumucheto tekinoroji chikuva kugadzira gomarara idzva kurapa kune vanhu vane gomarara rakaoma kurapa.

Iyo yakavhurika-label, chikamu 1/2 EVEREST-1 chidzidzo chiri kutarisa kuA2B530 senge ingangoita kurapwa kwemamota akasimba senge colorectal cancer, pancreatic cancer, uye. isina-diki kenza yemapapu kenza. Inotarisawo mamwe marudzi emamota akasimba anoburitsa CEA asi kwete HLA-A*02. Vanhu vave muchidzidzo cheEVEREST-1 vakatanga muchidzidzo cheBASECAMP-1 (NCT04981119), kwaiunganidzwa masero eT avo, akagadziriswa, uye akachengetwa kuti azoshandiswa gare gare.

Unogona kuda kuverenga: CAR T-Cell kurapwa kweyakawanda myeloma muChina

Chinangwa chikuru chechikamu chekutanga chekudzidza ndechekutsvaga yakachengeteka uye inoshanda zvakanyanya. Kuchengetedzeka uye kushanda nesimba kunofanirwa kuchengetedzwa sezvinangwa zvikuru zvechikamu chechipiri chekudzidza. Huwandu hwakasimba tumarara masero ayo akakurudzirwa dose anogona kuuraya achiri kuchengetedza masero ane hutano.

Colorectal cancer, rinova izwi kune ese ari maviri colon uye rectal cancer, zvinoitika apo polyps (mapoka emasero anokura pamwechete) anoumba mucolon kana rectum oshanduka kuita gomarara. Kuchembera, kuva mutema, kuve nenhoroondo yemapolyps kana gomarara mumuviri wako kana mumhuri yako, chirwere chebowel, genetics, chirwere cheshuga, kufutisa, kudya kwakajairika kwekuMadokero, uye kuputa nekunwa zvese zvinhu zvinoisa vanhu panjodzi.

Kuvhiya, radiation, kurapa kwakanangwa, uye immunotherapy ndiyo nzira dzakajairika dzekurapa cancer cancer. Zvakadaro, nzira zhinji dzemazuva ano dzegomarara iri nedzimwe dzine mamota akasimba dzinogona kuuraya varwere.

Unogona kuda kuverenga: CAR T Cell kurapwa mutengo muChina

Vatsvakurudzi vakashanda pachidzidzo ichi vanofunga kuti izvi CAR T-cell kurapa haina njodzi pane mamwe marapirwo anonangwa. Izvi zvinodaro nekuti CAR T-masero uraya bundu maseru pasina kukuvadza maseru ane hutano nekuti ane yakavakirwa-mukati yekuchengetedza switch inochengetedza hutano hutano kubva mukukuvadzwa.

Subscribe To Newsletter Vedu

Wana zvigadziriso uye usambopotsa blog kubva kuCancerfax

Zvimwe Kuti Uongorore

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.
kenza

Lutetium Lu 177 dotatate inotenderwa neUSFDA kune vana vane makore gumi nemaviri zvichikwira neGEP-NETS.

Lutetium Lu 177 dotatate, kurapwa kwepasi, ichangobva kugamuchira mvumo kubva kuUS Food and Drug Administration (FDA) yevarwere vevana, zvichiratidza chiitiko chakakosha muvana oncology. Mvumo iyi inomiririra chiedza chetariro kuvana vari kurwisana neuroendocrine tumors (NETs), isingawanzowanikwi asi inonetsa yegomarara iro rinowanzoratidza kuti rinoshingirira pakurapa kwakajairika.

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.
Chirwere chechirwere

Nogapendekin alfa inbakicept-pmln inotenderwa neUSFDA yeBCG-isingapindure isiri-muscle invasive cancer cancer.

"Nogapendekin Alfa Inbakicept-PMLN, chinyorwa che immunotherapy, chinoratidza vimbiso mukurapa gomarara redundira kana yasanganiswa neBCG therapy. Iyi nzira yekuvandudza yakanangana nemakaki egomarara uku ichisimudzira mhinduro ye immune system, ichiwedzera kushanda kwemishonga yechivanhu seBCG. Miedzo yemakiriniki inoratidza zvinokurudzira, zvichiratidza zvakavandudzwa mhedzisiro yemurwere uye kufambira mberi kunogona kuitika mukurapa kenza yedundira. Kuwirirana pakati peNogapendekin Alfa Inbakicept-PMLN neBCG kunozivisa nguva itsva mukurapa gomarara redundira.

Kuda rubatsiro? Chikwata chedu chakagadzirira kukubatsira.

Tinoshuvira kupora nekukurumidza kwemudiwa wako uye padyo neuyo.

Kutanga kutaura
Tiri paIndaneti! Taura Nesu!
Skena kodhi
Mhoro,

Kugamuchirwa kuCancerFax!

CancerFax ipuratifomu yekupayona yakatsaurirwa kubatanidza vanhu vakatarisana negomarara repamberi nekurapa kwesero seCAR T-Cell therapy, TIL kurapwa, uye miedzo yekiriniki pasi rese.

Tizivise zvatinogona kukuitira.

1) Kurapwa kwegomarara kunze kwenyika?
2) CAR T-Cell therapy
3) Mushonga wegomarara
4) Online vhidhiyo kubvunza
5) Proton kurapwa